Behavioural Health Development FDA Approval 
pharmaphorum
OCTOBER 2, 2020
“Modia is designed to close the gap as it relates to the access and receipt of quality, evidence-based therapeutic interventions and behavioural health services for individuals with OUD who participate in outpatient treatment with MAT,” said Michael Sumner, Orexo’s chief medical officer.
pharmaphorum
MARCH 21, 2022
In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co. in Japan announced their partnership to develop and commercialise prescription digital therapeutics and general wellness products to treat social anxiety disorder, generalised anxiety, and major depressive disorder.
Expert insights. Personalized for you.
98 
Let's personalize your content